TheracosBio aims to challenge Big Pharma blockbusters with newly-approved SGLT2 for diabetes
TheracosBio is squaring up for its little-engine-that-could moment. Its type 2 diabetes med Brenzavvy nabbed FDA approval on Friday, landing the privately-funded, little-known biotech in a big arena already populated by Big Pharma players.
Johnson & Johnson’s Invokana, AstraZeneca’s Farxiga, and Boehringer Ingelheim and Eli Lilly’s co-marketed Jardiance are long-established SGLT2 inhibitors. Invokana was first approved in 2013, followed by Jardiance and AstraZeneca in 2014, giving them a head start of almost a decade on Brenzavvy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.